Brooks Laboratories Ltd. | Small-cap | Healthcare
₹144.34
-1.25%
| Brooks Laboratories Stock Comparison:
Brooks Laboratories vs Sun PharmaceuticalBrooks Laboratories vs Divi's LaboratoriesBrooks Laboratories vs Sun Pharma AdvancedBrooks Laboratories vs Sequent ScientificBrooks Laboratories vs Gujarat ThemisBrooks Laboratories vs NIFTY 50 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Mar 2025

Income Metrics

Revenue 233.2M
Gross Profit 75.1M 32.19%
Operating Income 11.5M 4.94%
Net Income -14.6M -6.25%

Balance Sheet Metrics

Total Assets 1.2B
Total Liabilities 255.9M
Shareholders Equity 981.0M
Debt to Equity 0.26

Cash Flow Metrics

Revenue & Profitability Trend

Brooks Laboratories Income Statement From 2021 to 2025

Metric20252024202320222021
Revenue i825.6M790.1M624.8M900.9M770.4M
Cost of Goods Sold i540.7M610.6M612.2M758.0M552.4M
Gross Profit i284.8M179.5M12.6M142.9M218.0M
Gross Margin % i34.5%22.7%2.0%15.9%28.3%
Operating Expenses
Research & Development i-----
Selling, General & Administrative i-46.2M104.3M91.0M68.1M
Other Operating Expenses i105.8M148.0K3.9M10.8M2.3M
Total Operating Expenses i105.8M46.3M108.2M101.8M70.4M
Operating Income i33.4M14.4M-335.5M-217.0M-66.0M
Operating Margin % i4.0%1.8%-53.7%-24.1%-8.6%
Non-Operating Items
Interest Income i-736.0K921.0K877.0K1.7M
Interest Expense i10.3M7.2M19.5M28.3M31.0M
Other Non-Operating Income-----
Pre-tax Income i-97.9M-195.7M-383.7M-239.0M-89.9M
Income Tax i1.8M259.0K-73.2M-45.9M103.8M
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-99.7M-195.9M-310.5M-193.1M-193.7M
Net Margin % i-12.1%-24.8%-49.7%-21.4%-25.1%
Key Metrics
EBITDA i-71.6M-170.8M-299.0M-141.7M12.8M
EPS (Basic) i₹-3.72₹-7.65₹-12.57₹-7.67₹-7.03
EPS (Diluted) i₹-3.72₹-7.65₹-12.57₹-7.67₹-7.03
Basic Shares Outstanding i2679301125616000247030002518430424944833
Diluted Shares Outstanding i2679301125616000247030002518430424944833

Income Statement Trend

Brooks Laboratories Balance Sheet From 2021 to 2025

Metric20252024202320222021
Assets
Current Assets
Cash & Equivalents i434.0K1.3M232.0K26.0M8.8M
Short-term Investments i23.4M23.3M13.6M-2.2M-3.1M
Accounts Receivable i199.9M163.2M127.5M176.6M137.0M
Inventory i92.0M96.1M113.0M275.2M236.0M
Other Current Assets22.9M25.0K2.0K1.0K291.0K
Total Current Assets i338.8M310.5M276.1M611.8M473.6M
Non-Current Assets
Property, Plant & Equipment i139.7M3.3M3.1M74.1M52.5M
Goodwill i91.0K731.0K2.0M6.3M6.9M
Intangible Assets i91.0K731.0K2.0M6.3M6.9M
Long-term Investments-----
Other Non-Current Assets14.9M--44.0M-
Total Non-Current Assets i898.2M594.0M819.9M1.3B1.1B
Total Assets i1.2B904.5M1.1B2.0B1.6B
Liabilities
Current Liabilities
Accounts Payable i136.2M154.4M233.7M280.0M309.5M
Short-term Debt i62.1M52.9M59.1M151.2M169.4M
Current Portion of Long-term Debt-----
Other Current Liabilities8.1M1.0K11.4M1.0K1.0K
Total Current Liabilities i228.4M230.5M330.2M488.8M636.1M
Non-Current Liabilities
Long-term Debt i13.7M3.6M6.0M101.4M144.4M
Deferred Tax Liabilities i---032.3M
Other Non-Current Liabilities--1.0K1.0K1.0K
Total Non-Current Liabilities i27.5M18.1M26.2M127.1M193.1M
Total Liabilities i255.9M248.6M356.4M615.9M829.3M
Equity
Common Stock i294.6M262.5M247.0M247.0M247.0M
Retained Earnings i--386.8M-190.9M-236.2M-138.5M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i981.0M655.9M739.5M1.3B791.5M
Key Metrics
Total Debt i75.8M56.4M65.1M252.6M313.8M
Working Capital i110.3M80.0M-54.2M123.0M-162.5M

Balance Sheet Composition

Brooks Laboratories Cash Flow Statement From 2021 to 2025

Metric20252024202320222021
Operating Activities
Net Income i-97.9M-195.7M-383.7M-239.0M-89.9M
Depreciation & Amortization i-----
Stock-Based Compensation i-----
Working Capital Changes i21.0M-39.3M-2.0M-221.8M21.1M
Operating Cash Flow i-42.7M-234.4M-363.2M-432.9M-39.5M
Investing Activities
Capital Expenditures i-9.1M-4.4M-4.7M-203.1M-56.1M
Acquisitions i-436.6M--00
Investment Purchases i-14.7M---3.0M0
Investment Sales i----3.1M
Investing Cash Flow i-460.4M-4.4M-4.7M-250.0M-53.0M
Financing Activities
Share Repurchases i-----
Dividends Paid i-----
Debt Issuance i-----
Debt Repayment i-----
Financing Cash Flow i425.0M112.7M176.3M744.2M1.0K
Free Cash Flow i16.0M-101.2M-149.6M-606.6M-11.6M
Net Change in Cash i-78.0M-126.1M-191.6M61.3M-92.5M

Cash Flow Trend

Brooks Laboratories Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 310.21
Forward P/E 25.09
Price to Book 4.01
Price to Sales 4.80
PEG Ratio 25.09

Profitability Ratios

Profit Margin 2.25%
Operating Margin 10.72%
Return on Equity -10.16%
Return on Assets -8.06%

Financial Health

Current Ratio 1.48
Debt to Equity 7.73
Beta 0.71

Per Share Data

EPS (TTM) ₹0.47
Book Value per Share ₹36.34
Revenue per Share ₹32.49

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
brooks4.3B310.214.01-10.16%2.25%7.73
Sun Pharmaceutical 3.9T38.005.4715.08%19.29%3.26
Divi's Laboratories 1.6T70.8710.9114.64%23.89%0.03
Sun Pharma Advanced 47.4B-13.85-21.83157.88%-53.22%-1.24
Sequent Scientific 44.4B155.796.302.84%1.85%62.47
Gujarat Themis 43.3B96.8917.3919.64%30.17%12.27

Financial data is updated regularly. All figures are in the company's reporting currency.